Fact-checked by Grok 2 weeks ago

Myelography

Myelography is a diagnostic that involves the injection of a into the subarachnoid space surrounding the , followed by the use of or computed tomography () to produce detailed images of the , nerve roots, and . This technique allows for the evaluation of abnormalities such as herniated discs, , tumors, infections, and nerve compressions that may not be fully assessed by standard X-rays or when () is contraindicated or inconclusive. The concept of myelography was first proposed in 1919 by neurosurgeon Walter Dandy using air as a medium, though Jean-Athanase Sicard and Jacques Forestier described the modern oil-based method in 1921. Originally a primary spinal diagnostic tool, myelography has declined with the rise of MRI in the mid-1980s but remains relevant for specific cases like CSF leak detection, avulsions, and postoperative evaluations where MRI is limited (e.g., by artifacts or contraindications). Recent advancements, such as dynamic myelography as of 2025, have improved its precision for CSF leak localization. It offers benefits including high accuracy for issues— myelography shows up to 100% sensitivity for root avulsions in recent studies, often superior to MRI in challenging cases—and utility in patients with pacemakers or . However, risks include common post-procedure headaches from CSF leakage (up to one-third of cases), rare allergic reactions to (less than 1%), , , or . Overall, it serves as a safe, targeted tool in multimodal imaging approaches.

Overview

Definition and Purpose

Myelography is a diagnostic that involves the intrathecal injection of a contrast medium into the subarachnoid space, followed by radiographic using X-rays, , or computed tomography (CT) to visualize the , nerve roots, and surrounding structures. This technique provides detailed images of the by outlining the flow of (CSF) and highlighting any disruptions or abnormalities within the . The targets key anatomical components, including the , , exiting nerve roots, and the subarachnoid space, enabling precise evaluation of their integrity and relationships to adjacent tissues. The primary purpose of myelography is to identify and characterize spinal pathologies that may not be fully discernible with non-invasive imaging modalities like MRI, particularly in cases involving hardware artifacts or contraindications to magnetic fields. It is employed to detect conditions such as , impingement, tumors, herniated discs, infections, trauma-related injuries, , and CSF leaks, aiding in treatment planning and surgical decision-making. For instance, it excels in delineating the extent of disc herniations or stenotic changes that compress neural elements, providing critical information for interventions like decompression surgery. Originating in the early 20th century, myelography has evolved from rudimentary contrast techniques to a sophisticated adjunctive tool integrated with modern and fluoroscopic systems, enhancing its diagnostic accuracy while minimizing risks associated with earlier agents. Today, it remains valuable for complex cases where high-resolution visualization of dynamic CSF flow and neural is essential.

Historical Development

The concept of myelography was first proposed in 1919 by American neurosurgeon Walter Dandy, who suggested intrathecal injection of an opaque substance to visualize the spinal subarachnoid space, initially using air as a in a technique akin to . However, air myelography proved risky due to complications like severe headaches and meningeal irritation from gas introduction. In 1921, French physicians Jean-Athanase Sicard and Jacques Forestier introduced the first practical myelographic method by injecting Lipiodol, an iodized poppy seed oil, into the subarachnoid , enabling radiographic visualization of abnormalities such as tumors. During the and , Lipiodol gained widespread use but was criticized for its , which hindered complete removal and led to chronic irritation. By the 1940s, a shift occurred from air and early oil-based agents to improved oil contrasts; Pantopaque (iofendylate), introduced in 1944, offered better tolerability and easier aspiration but still posed risks of arachnoiditis, a fibrotic of the spinal , in some patients. The 1960s marked the advent of water-soluble ionic agents, such as and iothalamate, which absorbed more readily and reduced the need for oil removal, though they caused osmotic disturbances and . A major breakthrough came in 1972 with metrizamide, the first non-ionic water-soluble agent, which minimized irritation and allowed safer and injections. In 1976, myelography was pioneered, combining intrathecal with computed for enhanced multiplanar of spinal lesions. From the 1980s, the introduction of MRI drastically reduced myelography's routine use, as non-invasive imaging provided superior soft-tissue contrast without radiation or puncture risks. Modern non-ionic agents like , developed in the early 1980s, further improved safety by exhibiting low and rapid clearance. Despite this decline, myelography's historical role was pivotal, enabling precise preoperative localization of tumors and herniations in the pre-MRI era and advancing neurosurgical techniques through detailed anatomical insights.

Clinical Considerations

Indications

Myelography is primarily indicated for evaluating suspected , where it helps delineate the degree of canal narrowing and compression that may not be fully assessed by non-invasive imaging. It is also recommended for diagnosing herniation, particularly when there is clinical suspicion of impingement causing . Additionally, myelography aids in the detection of , such as meningiomas or metastatic lesions, by outlining mass effects on the and . Myelography is also indicated for detecting (CSF) leaks, such as in spontaneous intracranial hypotension, and evaluating avulsions in injuries. It aids in planning for . Inflammatory and infectious conditions represent key indications, including arachnoiditis, which presents with clumping of nerve roots, and spinal infections such as epidural abscesses, where myelography can confirm the extent of thecal sac involvement. Post-traumatic evaluations, such as assessing spinal cord contusions or dural tears following injury, benefit from myelography's ability to visualize subtle disruptions in CSF flow. For cerebrospinal fluid (CSF) dynamics issues, it is used to identify leaks or abnormal circulation, as in cases of spontaneous intracranial hypotension or post-surgical fistulas. Situational applications include pre-operative planning for spinal surgery, where detailed visualization of nerve root anatomy informs surgical approaches, and further evaluation of radiculopathy or myelopathy when MRI findings are inconclusive. Myelography is preferred over alternatives in scenarios requiring dynamic assessment of nerve root movement during positional changes or when MRI is contraindicated, such as in patients with non-MRI-compatible implants like pacemakers. These indications are supported by the American College of Radiology (ACR) Appropriateness Criteria, which rate CT myelography as "May Be Appropriate" for multilevel degenerative disease and suspected epidural abscess (as of the most recent available variants, referencing data up to 2019).

Contraindications

Myelography, an invasive procedure involving and intrathecal contrast administration, carries specific contraindications to minimize risks such as infection, hemorrhage, and neurological complications. Absolute contraindications include active (CNS) infection, such as , which poses a high risk of introducing pathogens into the subarachnoid space during puncture. Uncontrolled seizures represent another absolute contraindication due to the potential for exacerbation by contrast media or procedural stress. A recent or prior myelogram within 1 week is a relative contraindication to avoid cumulative risks of (CSF) leak or formation. Severe bleeding , exemplified by with platelet count below 50,000/μL, constitutes an absolute contraindication owing to the elevated hemorrhage risk associated with needle insertion. Relative contraindications encompass conditions where the procedure may proceed if benefits outweigh risks, following careful evaluation. These include , primarily due to fetal radiation exposure from , though shielding and minimization techniques can mitigate this. An uncooperative or agitated patient increases procedural difficulty and complication likelihood, serving as a relative contraindication. Connective tissue disorders, such as Ehlers-Danlos syndrome, heighten the risk of dural tear and CSF leakage, warranting caution. Additionally, generalized septicemia or localized infection at the puncture site represents a relative contraindication to prevent systemic spread. Patient-specific risks further inform contraindication assessment. Allergies to iodinated contrast media are a significant relative , potentially leading to severe anaphylactic reactions, though may allow proceeding in select cases. In patients with , myelography carries an elevated risk of symptom exacerbation or adverse neurological events from contrast interaction with demyelinated tissue. Historical or laboratory evidence of , such as elevated INR or recent antiplatelet therapy, also qualifies as relative, requiring correction where feasible. According to the American Society of (ASNR) practice parameter (2016), preprocedural evaluation must include assessment of status via recent platelet count, (PT), (PTT), and international normalized ratio (INR), alongside that explicitly outlines these contraindications and associated risks.

Types

Conventional Fluoroscopic Myelography

Conventional fluoroscopic myelography is a radiographic that involves the intrathecal injection of medium into the subarachnoid space, followed by real-time imaging under fluoroscopic guidance to visualize the , , and subarachnoid spaces. The procedure utilizes a tilting fluoroscopy table to manipulate the patient's position, allowing gravity to distribute the contrast dynamically through the for optimal opacification of targeted regions. This method provides direct assessment of contrast flow and filling defects in , enabling evaluation of spinal pathology such as cord compression, , or abnormalities. The process begins immediately after administration, with the radiologist using continuous to monitor the column as it moves cephalad or caudad via table tilting and . Multiple projections, including anteroposterior, lateral, and views, are acquired at various spinal levels to assess the and root sleeves comprehensively; spot films or digital are captured for . The entire sequence typically lasts 30 to 60 minutes, depending on the spinal region examined and the extent of . This dynamic approach allows for functional evaluation, such as observing leakage or positional changes in spinal structures. Historically, conventional fluoroscopic emerged as the primary diagnostic tool for spinal disorders following its introduction in 1921 by Jean-Athanase Sicard and Jacques Forestier, who first demonstrated the use of ; it dominated spinal imaging until the 1970s when began to supplant it. Despite the advent of , it remains relevant today for intraoperative guidance, cases where MRI is contraindicated, or basic evaluations in resource-limited settings. Key advantages include its ability to provide dynamic visualization of , which is particularly useful for detecting filling defects in sleeves and assessing mobility of spinal elements—features less effectively captured by static imaging modalities. It is also more cost-effective than CT-based alternatives, requiring only fluoroscopic equipment without advanced scanners. However, limitations encompass a higher dose compared to MRI (typically 3-7 mSv effective dose, varying by ), inferior depiction of bony anatomy due to overlapping structures, and image quality that is highly operator-dependent, influenced by patient cooperation and distribution.

CT Myelography

CT myelography is a diagnostic imaging technique that combines the intrathecal injection of iodinated contrast material into the cerebrospinal fluid (CSF) space with subsequent computed tomography (CT) scanning to produce detailed cross-sectional images of the spinal canal, cord, and nerve roots. The procedure typically begins with a lumbar puncture to introduce the contrast, allowing it to distribute within the subarachnoid space, followed by CT acquisition that enables multiplanar reconstructions in axial, sagittal, and coronal views for comprehensive visualization of spinal anatomy. This method enhances the detection of abnormalities by outlining the thecal sac and adjacent structures with high contrast resolution. First performed in 1976 by Giovanni Di Chiro and David Schellinger, myelography demonstrated its utility in evaluating spinal dysraphism through computer-assisted imaging after metrizamide injection, marking a significant advancement over earlier radiographic techniques. It rapidly became the gold standard for spinal imaging until the widespread adoption of (MRI) in the 1980s, though it remains relevant in specific clinical scenarios. The imaging process generally involves scanning 1-2 hours post-injection to capture optimal contrast opacification, facilitating the assessment of subtle pathologies such as CSF leaks, small intradural tumors, or postoperative spinal changes that may be obscured in other modalities. Compared to conventional fluoroscopic myelography, CT myelography offers superior depiction of interfaces and bony structures due to its inherent high-resolution capabilities, while certain protocols may reduce overall through targeted scanning. It also supports and rotational reconstructions, aiding in precise anatomical localization and surgical planning. Currently, it is preferred for evaluating spinal dysraphism, particularly when MRI is contraindicated or insufficient, as well as for confirming dynamic CSF dynamics or residual lesions in postoperative patients.

Regional Approaches

Myelography techniques are adapted based on the targeted spinal region to optimize contrast distribution and minimize risks, with the choice of puncture site influencing procedural safety and efficacy. The approach typically involves a lateral C1-C2 or C1-C3 puncture to access the upper directly, particularly when access is contraindicated or a complete subarachnoid block is suspected. This method requires precise needle placement in the dorsal subarachnoid space, often using a 22- or 25-gauge Quincke-type needle with the bevel oriented dorsally to reduce (CSF) leakage. A higher volume of nonionic , ranging from 7 to 12.5 mL (depending on concentration, such as 180-300 mg I/mL), is injected to ensure adequate opacification of the region. Risks include rare but serious complications like injury, with an incidence below 0.05%, potentially leading to bleeding or, in isolated cases, fatal outcomes from anomalous vascular anatomy. The lumbar approach remains the most common method, utilized in the majority of myelography procedures due to its relative accessibility and lower technical demands. It is performed at the L3-L4 or L4-L5 interspace, ideally below the (typically L2-L3 to L3-L4 for optimal CSF dynamics), via an interlaminar or paramedian route in the lateral decubitus or . A standard contrast bolus of approximately 10 mL is administered following a test injection of 0.5 mL to confirm intrathecal placement, allowing visualization of the and lower spinal structures. This approach is particularly suitable for beginners, as it benefits from fluoroscopic guidance and carries a lower risk profile compared to higher punctures, though postdural puncture (PDPH) remains a concern, mitigated by using smaller-gauge or atraumatic needles. Thoracic myelography is infrequently performed as a direct puncture due to anatomical challenges and is usually achieved indirectly through a injection combined with table tilting to direct contrast flow. In this rare approach, the patient is positioned prone or in decubitus Trendelenburg (head-down tilt of 10-15 degrees) to facilitate cranial migration of the 10 mL contrast bolus, enabling imaging of mid-spinal lesions such as tumors or CSF-venous fistulas. Fluoroscopic monitoring ensures controlled spread, avoiding excessive pressure on thoracic structures. Injection site selection depends on the spinal level of interest: lumbar punctures are preferred for lower thoracic and lumbosacral assessments, while punctures target upper regions, though crossover is feasible by manipulating positioning and table tilt to redistribute without additional injections. Outcomes vary by approach; direct punctures exhibit a lower PDPH incidence (milder and shorter duration, under 5% rate) compared to injections for cervical run-up, which can reach 38-52% rates due to greater CSF disturbance. approaches are safer for novice practitioners, with overall complication rates below 0.05% for major events when properly executed.

Special Populations

In pediatric patients, myelography requires tailored modifications to account for smaller body size and developmental considerations. Contrast agent doses are reduced and calculated based on body weight, typically ranging from 0.5 to 3 mL/kg for (Omnipaque 300 mgI/mL), with the usual dose being 1 to 1.5 mL/kg to minimize risks associated with limited (CSF) volume. Procedures often necessitate conscious or general to ensure cooperation and , particularly in younger children who may not tolerate the positioning or needle insertion. Common indications include evaluation of congenital spinal anomalies, such as tethered cord syndrome or spinal dysraphism, where myelography can delineate neural elements when MRI is inconclusive. Due to the invasive nature and smaller CSF compartment, pediatric patients face an elevated risk of post-procedural infection, including , compared to adults. For elderly patients, myelography adaptations address age-related physiological changes and comorbidities. Dosing of agents is generally lowered to reduce the likelihood of adverse effects like or CSF leakage, which can be exacerbated by reduced cardiovascular reserve and spinal degenerative changes such as . The procedure is frequently indicated for assessing or multilevel , where it provides detailed visualization of neural compression in patients unable to undergo MRI due to or implanted devices. Careful for postural is essential post-procedure, as older adults are more susceptible to orthostatic symptoms from CSF dynamics alterations. In other special populations, procedural challenges and risks are amplified. Obese patients present difficulties with fluoroscopic guidance and needle placement due to increased depth, often requiring longer needles or alternative imaging approaches to achieve accurate subarachnoid access. Myelography is generally avoided in pregnant individuals unless absolutely necessary for , owing to fetal risks; if performed, abdominal shielding is mandatory to mitigate . Immunocompromised patients, such as those with , experience heightened contraindications, particularly infection risks, necessitating stringent sterile techniques and prophylactic antibiotics, though the procedure may still be warranted for excluding . Guidelines emphasize body weight-based dosing and procedural safeguards across these groups. The European Society of Paediatric Radiology (ESPR), in collaboration with the European Society of Neuroradiology (ESNR), recommends ultrasound guidance for lumbar punctures in children under 12 months to optimize needle trajectory and reduce complications during myelography initiation. Overall, pediatric patients may experience a different profile of complications compared to adults, with higher rates of and fever but potentially lower incidence of headaches, though these may be more severe.

Procedure

Patient Preparation

Patient preparation for myelography involves several steps to minimize risks such as , allergic reactions, , and procedural discomfort while ensuring optimal imaging quality. These measures include dietary restrictions, medication adjustments, laboratory assessments, allergy screening, , logistical arrangements, and hydration protocols. Patients are typically instructed to remain nil per os () for solids for 2 to 4 hours prior to the to reduce the risk of , particularly if is anticipated, though clear liquids may be permitted up to 2 hours before. medications must be held in advance to prevent spinal ; for example, is discontinued 4 to 5 days prior with confirmation of a normal international normalized ratio (INR), while resumption occurs post-procedure under guidance. Anti-seizure medications are continued as prescribed to maintain therapeutic levels and reduce risk associated with contrast agents. Pre-procedure laboratory screening includes a coagulation panel (prothrombin time [PT], INR, partial thromboplastin time [PTT], and platelet count) within one week for patients with hematologic disorders, serum creatinine to assess renal function, and a detailed history of iodine allergies. These tests help identify contraindications such as or impaired function, which could increase bleeding or contrast-related risks. Informed consent is obtained after discussing the procedure's risks (e.g., , ), benefits, and alternatives such as (MRI). Patients are encouraged to hydrate with 1 to 2 liters of clear fluids the day before to promote renal clearance of contrast and reduce nephrotoxicity, especially in those with risk factors like . Logistical preparation includes establishing intravenous access for potential medications or hydration, preparing monitoring equipment for , and offering mild for anxious patients per ACR–SIR guidelines. Arrangements for post-procedure transportation are essential, as patients may experience temporary neurological effects and should not drive for 24 hours. The American College of Radiology (ACR) emphasizes pre-hydration strategies, such as intravenous saline at 1 to 1.5 mL/kg/hour starting 3 to 12 hours prior in high-risk patients, to mitigate contrast-induced .

Injection and Imaging Techniques

The myelography procedure commences with sterile access to the subarachnoid space via , typically performed at the L3-L4 interspace using a 22- to 25-gauge styletted spinal needle under fluoroscopic guidance to ensure precise placement. is administered prior to needle insertion, and upon traversing the dura, the stylet is removed to measure (CSF) pressure, which helps assess for any underlying intracranial or other abnormalities. A small test injection of 0.2 to 0.5 mL of contrast material is then administered to confirm intrathecal positioning and rule out inadvertent epidural or subdural placement. Following confirmation, nonionic iodinated contrast is injected slowly under continuous or intermittent fluoroscopic monitoring to prevent discomfort, turbulence, or extravasation, with rates generally on the order of 0.1 to 1 mL per second depending on the specific technique and patient tolerance. Total volumes range from 10 to 17 mL for lumbar approaches targeting the thecal sac, with reduced amounts (e.g., 7 to 12 mL) for cervical or thoracic studies to limit the iodine dose to a maximum of 3.0 g. To achieve optimal contrast distribution, the fluoroscopy table is tilted—often into the Trendelenburg position (head-down 15 to 30 degrees)—allowing gravity-assisted antegrade flow from the lumbar site upward to the desired spinal levels, or reverse tilting for retrograde flow in cervical injections. Patient positioning, such as prone or lateral decubitus, may be adjusted to enhance layering or target specific regions. Imaging acquisition occurs in real-time during injection via to visualize contrast dynamics, followed by multiplanar spot films in anteroposterior, lateral, and oblique projections to document and filling. For CT myelography, immediate post-injection scanning uses multidetector with thin collimation (0.6 to 1.0 mm slices), low (0.8), and multiplanar reconstructions to provide high-resolution detail of spinal . Throughout, are continuously monitored, and neurologic checks for sensation, motor function, and reflexes are performed at regular intervals to detect any immediate adverse effects. Procedural variations include antegrade flow for most lumbar-initiated studies or approaches via C1-C2 puncture when lumbar access is contraindicated, with the entire process typically lasting 45 to 90 minutes depending on the extent of and maneuvers. Quality control emphasizes prevention of through vigilant fluoroscopic oversight and test injections, with fluoroscopy-CT employed if initial views are suboptimal; historically, oil-based contrasts required of excess material post-, but modern water-soluble agents are naturally resorbed.

Post-Procedure Management

Following myelography, patients receive immediate post-procedure care to minimize risks such as post-dural puncture headache and leakage. This typically includes flat with the head in a neutral position for 1 to 4 hours to promote CSF resorption and reduce changes. Oral is encouraged, with patients advised to consume 2 to 3 liters of fluids, preferably caffeinated beverages, to replenish CSF volume and prevent headaches. In the recovery area, patients are monitored for 2 to 6 hours, during which , neurological status, and any signs of complications like or are assessed regularly. Discharge criteria generally include absence of severe , stable , and ability to ambulate without significant distress, allowing most low-risk patients to go home the same day. For follow-up, focuses on acetaminophen for mild discomfort, while patients are instructed to report symptoms such as fever, persistent , leg weakness, or changes in bowel/ function promptly. Imaging results are typically reviewed with the referring within 24 hours to discuss findings and next steps. Special instructions emphasize avoiding strenuous activity for 24 hours, refraining from driving if was used, and repeating laboratory tests if was administered to monitor renal function. According to the ACR-ASNR-SPR Practice Parameter for the Performance of Myelography and Cisternography (revised 2013, with ongoing relevance in current practice), outpatient procedures are feasible for low-risk patients, with same-day discharge supported when appropriate monitoring and instructions are provided.

Contrast Agents

Types and Properties

Contrast agents used in myelography have evolved significantly to minimize while maintaining diagnostic efficacy. Early agents included oil-based iodinated compounds such as iofendylate (Pantopaque), introduced in the , which provided persistent radiopacity but were adhesive and difficult to remove completely from the subarachnoid space, leading to a risk of chronic adhesive through mechanical irritation and inflammation of the arachnoid membrane. In the 1960s, ionic water-soluble agents like meglumine iothalamate emerged, offering better CSF miscibility than oils but exhibiting high osmolality (over 1500 mOsm/kg) and significant , including and due to their hypertonicity disrupting neuronal membranes. A pivotal advancement occurred in 1972 with metrizamide, the first non-ionic water-soluble agent, which reduced osmolality to around 300-500 mOsm/kg and lowered risk compared to ionic predecessors, though it still carried some neurotoxic potential, particularly in patients with seizure histories. Contemporary myelography relies on second-generation non-ionic water-soluble contrast media, such as (Omnipaque) and iopamidol (Isovue), which are the preferred agents for due to their low osmolality (500-850 mOsm/kg water) and minimal . These agents provide excellent radiographic opacification with iodine concentrations typically ranging from 180 to 240 mg/mL for myelographic use, allowing clear visualization of spinal structures while exhibiting low viscosity (e.g., 1.5-5 cP at 37°C depending on concentration) that facilitates smooth injection and even distribution within the (CSF). Their chemical stability in CSF ensures prolonged radiopacity without precipitation or degradation, and they are primarily excreted unchanged via glomerular filtration in the kidneys, with over 90% elimination within 24 hours. Selection of contrast agents for myelography is guided by safety profiles, with the U.S. (FDA) mandating non-ionic agents for all intrathecal applications since their approval in 1985, due to the and risks associated with high-osmolar ionic media. High-osmolar agents are contraindicated intrathecally because their osmotic effects can cause cerebral , blood-brain barrier disruption, and severe neurological complications. and iopamidol exemplify ideal properties: non-ionic structure minimizes chemotoxicity, low osmolality approximates plasma (285 mOsm/kg), and hydrophilicity reduces protein binding and neuronal irritation. The transition from ionic agents in the to non-ionic media in the and markedly improved , with studies reporting a reduction in adverse reaction rates from approximately 12-15% with ionic agents to 3% or less with non-ionic ones, including a substantial decrease in severe neurotoxic events like seizures and . This evolution, driven by pharmaceutical advancements, has made myelography safer for routine clinical use, though complete removal of residual contrast remains unnecessary due to rapid CSF clearance.

Administration Guidelines

The administration of agents in myelography requires precise dosing tailored to the injection , patient age, and procedure type to ensure diagnostic efficacy while minimizing risks. For lumbar myelography, typical volumes range from 10 to 17 mL of at 180 mg iodine/mL or 7 to 12.5 mL at 240 mg iodine/mL, delivering 1.8 to 3.06 g of iodine. myelography generally uses 6 to 12.5 mL of 240 mg iodine/mL or 4 to 10 mL of 300 mg iodine/mL, corresponding to 1.2 to 3.0 g of iodine. Thoracic and total columnar approaches follow similar ranges, with 6 to 12.5 mL of 240 mg iodine/mL or 6 to 10 mL of 300 mg iodine/mL, up to 3.0 g of iodine. The maximum total iodine dose should not exceed 3.06 g across all procedures, as recommended by manufacturer guidelines and FDA approvals to prevent . Pediatric dosing is prorated based on body weight and age to account for smaller CSF volumes, with total iodine limited to 0.36 to 2.7 g. For example, children under 3 months receive 2 to 4 mL of 180 mg iodine/mL (0.36 to 0.72 g iodine), while those aged 7 to 13 years may receive 5 to 12 mL (0.9 to 2.16 g iodine), approximating 1 mL per 5 kg of body weight adjusted for the specific concentration. Higher iodine concentrations, such as 300 mg iodine/mL, are suitable for myelography to enhance opacification, but volumes must remain within these limits. Injection techniques emphasize safety and controlled delivery. must be administered slowly over 1 to 2 minutes under fluoroscopic guidance following confirmation of (CSF) aspiration to verify needle placement in the subarachnoid space. Only non-ionic, low-osmolality agents approved by the FDA for intrathecal use, such as (Omnipaque) or iopamidol (Isovue-M), are permitted, as ionic agents carry high risks of severe adverse effects when injected intrathecally. Post-injection, the needle is removed, and the site is monitored; a may be used to clear residual from the needle tract if needed. During administration, continuous monitoring for signs of patient distress is essential. The procedure should be paused immediately if severe , neurological changes, or seizure-like activity occurs, allowing for and potential . Patients with a history of mild allergic reactions to may receive premedication, such as oral (50 mg at 13, 7, and 1 hours prior) and diphenhydramine (50 mg 1 hour prior), to mitigate risks, though evidence for efficacy in intrathecal use remains limited compared to intravenous applications. Regulatory standards mandate storage of these agents at room temperature (15-30°C or 20-25°C, protected from ), with a typical of 3 to 5 years from manufacture, ensuring stability for clinical use. Recent updates in professional guidelines reinforce conservative dosing to enhance safety. FDA and manufacturer guidelines limit total intrathecal iodine to 3.06 g to reduce risks, aligning with maxima in package inserts and reflecting from clinical studies on neurotoxic thresholds. These protocols apply across conventional fluoroscopic and myelography, with brief consideration for regional approaches such as injection sites where volumes are further reduced.

Risks and Complications

Common Adverse Effects

The most common adverse effect following myelography is post-dural puncture (PDPH), with an incidence ranging from 30% to 50% of patients. This positional , characterized by worsening upon upright and relief when , typically onset within 12 to 24 hours after the and lasts 1 to 7 days. It results from leakage through the dural puncture site, leading to intracranial hypotension. Initial management involves conservative measures such as bed rest and hydration, with considered for severe or persistent cases; detailed strategies are outlined in post-procedure management protocols. Nausea and vomiting occur in approximately 10% to 20% of cases, primarily due to meningeal irritation from the injected . These symptoms are usually mild and self-limiting, resolving within 24 hours without specific intervention. Back or is reported in 20% to 30% of patients, often attributable to the needle insertion or contrast distribution along the , and is typically managed with nonsteroidal anti-inflammatory drugs (NSAIDs). Other mild effects include low-grade fever and rigors, which may arise from transient inflammatory responses to the or procedural . According to studies, PDPH incidence is highest with the lumbar approach, reaching up to 40%. These common effects are generally benign and do not require escalation beyond routine monitoring, distinguishing them from rarer severe complications.

Rare and Serious Risks

Seizures represent a rare but serious complication of myelography, occurring in 0.093%–0.847% of cases when using modern nonionic agents. Historically, the incidence was higher, reaching up to 5% with ionic , though such agents are no longer in use. Risk factors include patient , high doses, history of , and inadvertent intracranial migration. Infectious complications, particularly bacterial , arise from breaches in sterile technique during the procedure, with an estimated incidence of 0.01%–0.1%. These infections typically involve streptococcal species from oral or respiratory introduced via healthcare personnel, as evidenced by outbreaks linked to absent facemask use. Prophylaxis emphasizes strict , including surgical masks for providers; antibiotics may be indicated in high-risk scenarios such as immunocompromise. Neurological sequelae are infrequent but can be severe. , characterized by inflammation and adhesions in the subarachnoid space, occurs in less than 0.1% of cases after the shift to water-soluble nonionic agents, largely a legacy of earlier oil-based contrasts like iophendylate. , potentially leading to cord compression, is extremely rare, primarily reported in case studies, and strongly associated with underlying . has been documented in isolated case reports, particularly in patients with preexisting , where contrast injection exacerbates cord ischemia or compression. Other grave risks include anaphylactic reactions to the , with severe cases like occurring in fewer than 0.01% of procedures. Renal failure may ensue in patients with preexisting kidney impairment due to the load, though this is mitigated by protocols. Death is exceedingly rare, with rates below 0.001%, typically tied to unmanaged or profound neurological events. Overall, major complications from myelography are infrequent (less than 1% based on practitioner surveys), underscoring the procedure's relative safety when performed by experienced practitioners. is mandatory, with patients counseled on these low-probability, high-impact risks to ensure shared decision-making.

Current Role and Alternatives

Decline Due to MRI

The introduction of (MRI) in the mid-1980s marked a pivotal shift in spinal imaging, significantly diminishing the role of myelography due to MRI's non-invasive nature, absence of and intrathecal contrast requirements, and superior soft tissue contrast for visualizing the and nerve roots. Prior to this, myelography had been the primary modality for evaluating pathologies since the early , but MRI's ability to provide multiplanar images without patient repositioning rapidly established it as the preferred first-line technique. MRI offers several key advantages over myelography, including the elimination of intrathecal injection risks such as leakage and chemical irritation, as well as enhanced detection of subtle abnormalities like cord and through its high-resolution depiction of soft tissues. Unlike myelography, which relies on or computed tomography () for imaging and exposes patients to radiation doses typically ranging from 3-4 mSv for procedures, MRI avoids such exposure entirely. Additionally, MRI's non-invasive approach reduces procedural complexity and improves patient comfort, with no need for specialized contrast administration or strict positioning during acquisition. In contrast, myelography's invasive procedure—involving —carries a notable risk of post-dural puncture from CSF leakage, occurring in up to 30% of cases. Its limited availability stems from the need for fluoroscopic suites and trained personnel, further contributing to its decline as MRI scanners became more widespread. The American College of Radiology (ACR) Appropriateness Criteria reinforce MRI as usually appropriate for initial evaluation of conditions like and , positioning myelography as a secondary option only in select scenarios. Usage of myelography has plummeted since the 1980s; for instance, citations related to the procedure decreased from 3,226 in the 1980-1989 decade to 987 in 2000-2009, reflecting broader clinical shifts. At one major institution, annual myelography volumes fell from 400 in 1999 to 171 in 2009, a decline exceeding 55%, underscoring MRI's dominance in routine spinal diagnostics. While myelography retains utility in cases of MRI failure, such as severe motion artifacts, its overall prevalence has contracted to a niche role in modern .

Remaining Indications

Myelography remains a valuable diagnostic tool in cases where magnetic resonance imaging (MRI) is contraindicated, such as in patients with non-MRI-conditional pacemakers, cochlear implants, or severe claustrophobia. The increasing availability of MR-conditional implants has reduced the number of absolute contraindications since the 2010s. In these scenarios, computed tomography (CT) myelography provides detailed visualization of the spinal canal, nerve roots, and thecal sac without the risks associated with magnetic fields or confined spaces. Beyond contraindications, myelography offers enhanced detail in specific conditions requiring dynamic assessment or where MRI is limited, such as (CSF) leaks, where dynamic myelography captures real-time contrast flow to localize high-flow leaks or ventral dural tears that static imaging may miss. It is also preferred for postoperative evaluation of spinal hardware, as metallic implants cause significant MRI artifacts that obscure neural structures, whereas myelography delineates hardware position, fusion integrity, and adjacent soft tissues effectively. Additionally, in traumatic injuries, myelography excels at detecting subtle avulsions, including pseudomeningoceles and intradural defects, with high sensitivity for preoperative planning. In surgical planning, myelography supports procedures like correction by highlighting foraminal and lateral recess in degenerative cases, aiding in precise and instrumentation decisions. For tumor resection, particularly in metastatic epidural , CT myelography assists in delineating involvement when MRI is inconclusive, facilitating separation techniques. Intraoperative or preoperative CT myelography with further enhances accuracy in complex deformities by providing myelographic detail integrated with bony . Emerging applications include digital subtraction myelography combined with for identifying CSF-venous fistulas, a type of vascular anomaly causing spontaneous intracranial hypotension, where real-time subtraction isolates subtle contrast extravasation into epidural veins. Recent outpatient protocols for dynamic myelography have demonstrated high procedural success, with studies reporting effective leak localization in over 90% of cases while minimizing and enabling same-day discharge. Looking ahead, myelography may see revival through AI-enhanced imaging, such as patch-based models that generate virtual myelograms from dual-energy scans to improve CSF delineation and reduce contrast needs in complex cases. It serves as an adjunct in intricate spinal evaluations, particularly for failed fusions or multilevel pathologies where MRI falls short.

References

  1. [1]
    Myelography (Myelogram) - Radiologyinfo.org
    Myelography is an imaging examination that involves the introduction of a spinal needle into the spinal canal and the injection of contrast material in the ...
  2. [2]
    Myelography in the Age of MRI: Why We Do It, and How We Do It - NIH
    The method that we know as “myelography” was first described by Sicard and Forestier [1] in 1921; by the end of the 1920s, it had become an established ...
  3. [3]
    Myelogram - University of Rochester Medical Center
    A myelogram is a diagnostic imaging test generally done by a radiologist. It uses a contrast dye and X-rays (fluoroscopy) or computed tomography (CT) to look ...Missing: definition | Show results with:definition
  4. [4]
    Myelography: MedlinePlus Medical Test
    Aug 27, 2024 · Myelography is an imaging test to check for problems in your spinal canal. It uses a type of x-ray called fluoroscopy or a CT scan with ...
  5. [5]
    Myelogram | Johns Hopkins Medicine
    A myelogram, also known as myelography, is a procedure that combines the use of dye with x-rays or CT scans to examine the spinal canal. Learn more.
  6. [6]
    [PDF] Myelography.pdf - American Society of Neuroradiology
    4. Diagnostic evaluation of spinal or basal cisternal disease. 5. Nondiagnostic MRI studies of the spine or skull base. 6 ...
  7. [7]
    Myelography and the 20th Century Localization of Spinal Cord ...
    Sep 1, 2020 · The Rise of Myelography ... In 1919, American neurosurgeon Walter Dandy (1886–1946) first proposed the intrathecal injection of a substance opaque ...Missing: evolution | Show results with:evolution
  8. [8]
    Contrast Myelography Past and Present | Radiology - RSNA Journals
    Thirty years ago (1919) Dr. Walter E. Dandy (1), in describing the use of air for the roentgenographic visualization of the ventricles of the brain, observed ...
  9. [9]
    Myelography and the 20th Century Localization of Spinal Cord ...
    Sep 1, 2020 · In 1944, a team of clinicians and scientists from the University of Rochester, NY, reported their experience with a new oil-based myelographic ...
  10. [10]
    [PDF] History of Contrast Media - Journal of Clinical Practice and Research
    Jun 1, 2021 · Water-soluble triiodinated compounds derived from triiodobenzoic acid were developed from 1953 onwards (3). Diatrizoate (Radioselectan®), ...
  11. [11]
    Metrizamide - an overview | ScienceDirect Topics
    A great advancement came along in 1972 with the introduction of metrizamide (Amipaque), a well-tolerated water-soluble myelographic contrast agent.21 ...
  12. [12]
    CT myelography | Radiology Reference Article - Radiopaedia.org
    Mar 11, 2023 · History. CT myelography was first performed in 1976 2 and became the gold standard for imaging the spinal canal and cord until the advent of ...
  13. [13]
    Myelography in the Age of MRI: Why We Do It, and How ... - PubMed
    Since the introduction of magnetic resonance imaging into clinical routine in the mid-1980s, the role of myelography seemed to be constantly less important in ...Missing: iohexol decline
  14. [14]
    Myelogram: What It Is, Procedure, Results & Side Effects
    A myelogram is an imaging test that uses a contrast material and X-rays or computed tomography (CT) scans to get detailed pictures of your spine.
  15. [15]
    None
    Nothing is retrieved...<|separator|>
  16. [16]
    Preview
    ### Summary of Myelography Indications from ACR Appropriateness Criteria for Low Back Pain
  17. [17]
    Myelopathy - AC Search - American College of Radiology
    In spondylotic myelopathy, conventional myelography can be used to diagnose severe canal stenosis [74]. MRI, however, is best for evaluation of the marrow and ...
  18. [18]
    Lumbar Spine Imaging - StatPearls - NCBI Bookshelf
    Jan 15, 2020 · [8] Contraindications for CT myelogram include pregnancy and other general contraindications for a lumbar puncture, such as severe bleeding ...<|control11|><|separator|>
  19. [19]
    [PDF] OMNIPAQUE™ (iohexol) Injection 140 180 240 300 350 140 350 ...
    alcoholism, or multiple sclerosis. Elderly patients may present a greater risk following myelography. The need for the procedure in these patients should be ...
  20. [20]
    CT Myelography: Clinical Indications and Imaging Findings
    CT myelography is an important imaging modality that combines the advantages of myelography and the high resolution of CT.Missing: evolution | Show results with:evolution
  21. [21]
    Computed Tomography of Spinal Cord After Lumbar Intrathecal ...
    Jul 1, 1976 · Computed Tomography of Spinal Cord After Lumbar Intrathecal Introduction of Metrizamide (Computer-Assisted Myelography). Giovanni Di Chiro, ...
  22. [22]
    Neuroradiology Back to the Future: Spine Imaging - PMC
    CT myelography is useful in the postoperative spine, with fewer artifacts related to surgical hardware than MR imaging, and in assessing spinal canal stenosis, ...Missing: definition | Show results with:definition
  23. [23]
    Myelography: Still the Gold Standard - PMC - NIH
    Most surgeons recognize the superiority of CT myelography in visualizing bony pathologic abnormality in both the cervical and lumbar spine. However, MR imaging ...
  24. [24]
    Three-Dimensional Rotational Myelography - PMC - NIH
    Compared with CT myelography, 3D rotational myelography provides immediate rotational images and 3D reconstruction without transferring the patient to another ...
  25. [25]
    Incidence of Spinal CSF Leakage on CT Myelography in Patients ...
    Dec 6, 2021 · In the present study, we detected leaks in 80% patients with nontraumatic SDH who underwent CT myelography to rule out suspected SIH. This rate ...
  26. [26]
    The Lateral C1–C2 Puncture: Indications, Technique, and Potential ...
    Serious complications after C1–C2 puncture are rare [19, 22]. A large survey by Robertson and Smith [22] revealed major complications in less than 0.05% of ...
  27. [27]
    [PDF] CT Myelography: How to Do It - UNC Radiology
    4. Review the main indications of CTM and present characteristic imaging findings, especially in the evaluation of spontaneous intracranial hypotension (SIH).
  28. [28]
    ACR–ASNR–SPR Practice Parameter for the Performance of ...
    Myelography has been an important diagnostic modality for a wide range of spinal disease processes for more than 80 years. Cisternography using intrathecal ...
  29. [29]
    Myelography With Iohexol (Omnipaque); A Clinical Report ... - PubMed
    Headache occurred in 38%. The highest frequency of headache (52%) was reported following cervical myelography with lumbar puncture technique, placing the ...Missing: approach percentage
  30. [30]
    C2 Spinal Puncture Training - American Journal of Neuroradiology
    Jun 15, 2023 · 3 While lateral C1–C2 spinal puncture is consid- ered a safe procedure when performed by a skilled radiologist, with ,0.05% of cases having a ...
  31. [31]
    [PDF] ACR–ASNR–SPR Practice Parameter for the Performance ...
    10. Contraindications to myelography. 11. Knowledge of the drugs that can increase the risk of myelographic adverse events.
  32. [32]
    Sequelae of metrizamide myelography in 200 examinations
    One striking finding was the much more common occurrence of temperature elevation among the pediatric group. (15% pediatric versus. 8% adult). ... in pediatric.
  33. [33]
    Vertebral Fracture - StatPearls - NCBI Bookshelf - NIH
    Elderly patients or those with osteoporosis or who are at risk of osteoporosis ... A CT myelogram is an option for patients unable to obtain an MRI.
  34. [34]
    Misdiagnosis of Spontaneous Intracranial Hypotension
    Patients with spontaneous intracranial hypotension are commonly misdiagnosed, causing a significant delay in the initiation of effective treatments.
  35. [35]
    Difficult Lumbar Puncture
    Our standard needle is 22 ga. For extremely obese patients, we often use a 3.5-inch 18-ga introducer, but this larger gauge should not enter the thecal sac.
  36. [36]
    Myelogram | Cedars-Sinai
    You may need to stop these medicines before the procedure. Tell your provider if you have heart disease, asthma, thyroid problems, kidney disease or diabetes.Missing: contraindications renal impairment
  37. [37]
    Myelography in patients with acquired immuno deficiency syndrome
    Myelography is not essential for establishing the diagnosis, which is based on cerebrospinal fluid (CSF) analysis, but may be indicated to exclude a spinal cord ...
  38. [38]
    European recommendations on practices in pediatric neuroradiology
    Sep 5, 2022 · This is a consensus document providing recommendations based on expert opinion and best available evidence, regarding the optimal conditions for the safe ...Missing: myelography | Show results with:myelography
  39. [39]
    [PDF] Myelogram - Stanford Medicine
    Mar 8, 2016 · The dye used during the procedure may cause and allergy, seizure, or brain problems. The dye may also damage your kidneys. GETTING READY: ...Missing: contraindications impairment
  40. [40]
    About Your Myelogram | Memorial Sloan Kettering Cancer Center
    Nov 22, 2024 · What is a myelogram? A myelogram is an imaging test of the spinal cord, nerves, and the tissues around them.
  41. [41]
    Myelogram: Overview, Preparation Tips & Side Effects
    A myelogram procedure shows the passage of contrast material in the space around the spinal cord using fluoroscopy, so organs can be seen over time.
  42. [42]
    History of myelography with pantopaque contributing to arachnoiditis
    Aug 28, 2014 · The only method available for analyzing the contents of the spinal canal was myelography using Pantopaque injected into the spinal fluid as a contrast agent.Missing: 1944 | Show results with:1944
  43. [43]
    Iofendylate - an overview | ScienceDirect Topics
    Pantopaque, an oily ... Several studies have clearly associated an increased risk of arachnoiditis in patients who have undergone prior spine surgeries.
  44. [44]
    Ionic Contrast Medium - an overview | ScienceDirect Topics
    Iodinated contrast media are either ionic or non-ionic, and they are further classified by their osmolality. The first-generation contrast media are ionic high- ...
  45. [45]
    contrast agents used in the past, present, and future - PubMed
    Pantopaque was replaced by metrizamide, a more advanced contrast agent. Now iohexol, an even safer contrast material, may be the ideal radiographic agent of the ...
  46. [46]
    Myelography - an overview | ScienceDirect Topics
    The use of myelography has decreased significantly due to the invasive nature of the procedure and the availability of other noninvasive imaging tools, ...
  47. [47]
    Critical Assessment of Myelography Practices: A Call for Rational ...
    Potential complications of myelography include infection, hemorrhage, nerve injury, and, reportedly, postmyelographic seizures in patients taking certain ...
  48. [48]
    iohexol injection, solution OMNIPAQUE - DailyMed - NIH
    140 mg IODINE/mL and 350 mg IODINE/mL Use only the OMNIPAQUE iodine concentrations and presentations recommended for intrathecal procedure.
  49. [49]
    Omnipaque (Iohexol Injection): Side Effects, Uses, Dosage ... - RxList
    OMNIPAQUE 140, OMNIPAQUE 180, OMNIPAQUE 240, OMNIPAQUE 300, and OMNIPAQUE 350 have osmolalities from approximately 1.1 to 3.0 times that of plasma (285 mOsm/kg ...
  50. [50]
    Iohexol: Uses, Interactions, Mechanism of Action | DrugBank Online
    Iohexol is an effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other ...
  51. [51]
  52. [52]
    The Adoption of Low-Osmolar Contrast Agents in the United States
    Apr 6, 2012 · In 1985, the Food and Drug Administration. (FDA) approved three LOCAs in the Unit- ... ionic and nonionic contrast media: a report from the ...
  53. [53]
    Isovue-M (Iopamidol Injection): Side Effects, Uses, Dosage ... - RxList
    Isovue-M (iopamidol) Injection is a contrast medium used for intrathecal administration in neuroradiology including myelography (lumbar, thoracic, cervical, ...
  54. [54]
    Iopamidol - an overview | ScienceDirect Topics
    The usual recommended adult dose range for iopamidol when performing myelographic procedures is 2000 to 3000 mg iodine. This is equivalent to 10 to 15 mL Isovue ...
  55. [55]
    Adverse reactions to ionic and nonionic contrast media. A report ...
    It is concluded that nonionic contrast media significantly reduce the frequency of severe and potentially life-threatening ADRs to contrast media at all levels ...
  56. [56]
    A prospective trial of ionic vs nonionic contrast agents in routine ...
    We conclude that nonionic agents cause fewer and less severe adverse effects. Reducing adverse effects can save the patient or the examining site either time ...
  57. [57]
    Iohexol Dosage Guide + Max Dose, Adjustments - Drugs.com
    The usual recommended total doses for lumbar, thoracic, cervical, and/or total columnar myelography by lumbar puncture in children are 0.36 gI to 2.7 gI. Actual ...
  58. [58]
    ISOVUE-M 200 - DailyMed
    Overdosage. A dose of 3000 mgl in adults and 2400 mgl in children is sufficient for most myelographic procedures. Doses above these levels may result in an ...
  59. [59]
    [PDF] ACR Manual on Contrast Media 2024
    Prophylactic hydration to protect renal function from intravascular iodinated contrast material in patients at high risk of contrast-induced nephropathy ...Missing: myelography | Show results with:myelography
  60. [60]
    Safety and Technical Performance of Bilateral Decubitus CT ...
    Dec 20, 2024 · Myelography Technique​​ Either 10 or 20 mL of iodinated contrast media is then injected. The patient is monitored for adverse effects that might ...<|control11|><|separator|>
  61. [61]
  62. [62]
    Outpatient lumbar myelography. Analysis of complications after ...
    The complication rate was 37% in the hospitalized patients and 40% in the outpatients. Adverse reactions, mostly in the form of headache, were very mild in ...Missing: pediatrics adults
  63. [63]
    Outpatient Myelography: A Prospective Trial Comparing ... - NIH
    Myelography is normally performed as an inpatient procedure in most hospitals in Japan. No studies have reported the usefulness and adverse effects of ...Missing: definition | Show results with:definition<|control11|><|separator|>
  64. [64]
    Safety of Consecutive Bilateral Decubitus Digital Subtraction ...
    Oct 1, 2020 · The rates of minor adverse effects such as pain (27.2%), nausea (8.1%), and other minor transient neurologic effects (5.1%) were comparable ...
  65. [65]
    [PDF] Hyperthermia after Metrizamide Myelography - NCBI
    The degree of fever was mild in two or three cases, 39°C- 39.5°C in most, and one patient developed a fever of 40.5°C. The fever lasted 4-6 hr in all cases.Missing: rigors | Show results with:rigors<|separator|>
  66. [66]
    morbidity in patients with previous intolerance to iodine derivatives in
    The cause of chills and fever after all types of myelography has always been an enigma. We believe that dose-related toxicity, the overall medical status of the ...Missing: rigors | Show results with:rigors
  67. [67]
    Myelography in the Assessment of Degenerative Lumbar Scoliosis ...
    Myelography has been shown to highlight foraminal and lateral recess stenosis more readily than computed tomography (CT) or magnetic resonance imaging (MRI).
  68. [68]
    Incidence of and risk factors for seizures after myelography ...
    May 15, 2011 · Objective—To establish the incidence of and risk factors for seizures following myelography performed with iohexol in dogs.Missing: rates | Show results with:rates
  69. [69]
    Expert Opinion: Streptococcal Meningismus After CT Myelograp
    Feb 19, 2015 · Streptococcal meningitis is a potential complication of myelography. Healthcare personnel and patients should be advised of this risk as well ...Missing: prophylaxis | Show results with:prophylaxis
  70. [70]
    Outbreak of Bacterial Meningitis Among Patients Undergoing ...
    Three bacterial meningitis cases (2 confirmed, 1 probable) were identified among 9 patients who underwent myelograms at clinic A from October 11 to 25, 2010. No ...
  71. [71]
    Outbreak of Bacterial Meningitis Among Patients Undergoing ...
    Bacterial meningitis likely occurred because HCP performing myelography did not wear facemasks; lapses in injection practices may have contributed to ...
  72. [72]
    Thoracic arachnoiditis, arachnoid cyst and syrinx formation ... - NIH
    Spinal arachnoiditis can rarely occur following irritation from foreign body substances, including certain oil based contrast agents used for myelography.Missing: incidence | Show results with:incidence
  73. [73]
    Incidence of postoperative symptomatic epidural hematoma in ...
    May 6, 2011 · There are reports concerning SEH after spinal surgery, and the incidence of hematoma evacuation after spine surgery ranges from 0.1% to 0.2%.
  74. [74]
    Post-myelography paraplegia in a woman with thoracic stenosis - NIH
    We report a rare case of transient paraplegia following myelography in a woman with thoracic stenosis. Findings. A 51-year-old woman, 20 months status post- ...
  75. [75]
    Contrast media adverse reactions | Radiology Reference Article
    Oct 13, 2025 · Prognosis. The estimated mortality rate due do adverse contrast media reactions ranges between 2 to 9 cases per 1 million administrations 3.
  76. [76]
    Anaphylaxis to Iodinated Contrast Material: Nonallergic ...
    The frequency of mild anaphylactic reactions ranges from 3.8% to 12.7% in patients receiving high-osmolar ionic contrast material and 0.7% to 3.1% in patients ...
  77. [77]
    Analysis of patient doses for myelogram and discogram ... - PubMed
    Effective doses for lumbar myelograms were 3-4 mSv and for cervical myelograms and discograms were 1 mSv.
  78. [78]
    Analysis and Prediction of Claustrophobia during MR Imaging with ...
    The overall claustrophobic event rate was 9.8% (640 of 6520; 95% confidence interval [CI]: 9.1, 10.6). The CLQ did not induce claustrophobic events because the ...
  79. [79]
    Dynamic CT Myelography: A Technique for Localizing High-Flow ...
    The dynamic CT myelographic technique we describe requires CT imaging during the injection of diluted myelographic contrast material. Thus, the infusion of ...
  80. [80]
    Postoperative Spinal CT: What the Radiologist Needs to Know
    Oct 7, 2019 · Although postoperative spinal CT is often limited owing to artifacts caused by metallic implants, parameter optimization and advanced metal ...
  81. [81]
    [PDF] Intraoperative CT Myelography in Correction of Spinal Deformity
    Intraoperative CT myelography is a useful adjunct to image guided surgical correction of spine deformity, and can obviate the need for a more extensive open ...
  82. [82]
    Introduction to Digital Subtraction Myelography for CSF-Venous ...
    Jan 8, 2025 · The purpose of this video is to introduce digital subtraction myelography for CSF-venous fistula (CVF) detectection.
  83. [83]
    Myelographic Techniques for the Localization of CSF-Venous Fistulas
    Aug 1, 2024 · In this article, we review the spectrum of imaging modalities available for the detection of CVFs, explain the advantages and disadvantages of ...
  84. [84]
    Virtual CT Myelography: A Patch-Based Machine Learning Model to ...
    Aug 31, 2022 · In this study, we developed a novel machine learning model to assist the visualization of intraspinal soft tissue structures on an unenhanced ...
  85. [85]
    [PDF] EviCore Spine Imaging Guidelines - V1.1.2025 - Effective 02/14/2025
    Feb 14, 2025 · These studies may be helpful in the evaluation of complex failed spinal fusion cases or needed for preoperative surgical planning when the ...